{"id":"W4410799942","doi":"10.1016/s1470-2045(25)00158-5","title":"Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 study","year":2025,"lang":"en","type":"article","venue":"The Lancet Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Astellas Pharma; Seagen; Pfizer","keywords":"Pembrolizumab; Urothelial cancer; Medicine; Open label; Oncology; Internal medicine; Chemotherapy; Phases of clinical research; Cancer; Clinical trial; Immunotherapy; Bladder cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001368781,0.001006928,0.002487493,0.000304397,0.0002686729,0.0009244538,0.0007161266,0.001114047,0.003174116],"category_scores_gemma":[0.001306645,0.0004296963,0.001939659,0.0003433496,0.0008095109,0.001077584,0.0003511519,0.002729055,0.0004801047],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007712521,"about_ca_system_score_gemma":0.0007401158,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001247236,"about_ca_topic_score_gemma":0.003155528,"domain_scores_codex":[0.9994235,0.0003322166,0.00002598637,0.00008317757,0.00003942862,0.00009569616],"domain_scores_gemma":[0.9992489,0.0002664737,0.0001785916,0.00004426525,0.00003131894,0.0002303794],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9673284,0.004862177,0.0008453089,0.0006580316,0.001277353,0.00003408931,0.00006344431,0.0006300681,0.002344002,0.00009577165,0.0004962003,0.02136513],"study_design_scores_gemma":[0.836713,0.1538352,0.00604518,0.00008850167,0.001030529,0.00005409518,0.00006864833,0.0007415357,0.0004934894,0.0002047109,0.0007016013,0.00002351957],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9927413,0.004808374,0.0001945054,0.0003127431,0.0002336169,0.0004466055,0.0003788633,0.00003235897,0.0008516043],"genre_scores_gemma":[0.9943315,0.002331151,0.0004295388,0.0004718963,0.0001653934,0.0004878486,0.0005240862,0.00001025996,0.001248369],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003174116,"threshold_uncertainty_score":0.01061851,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05422273485756478,"score_gpt":0.404647357926723,"score_spread":0.3504246230691582,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}